Automated Fill and Finish System

Thermo Fisher Scientific has introduced the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated, functionally closed instrument designed to support formulation and filling steps in cell therapy manufacturing. The system helps reduce manual handling of patient derived cells by providing a compact, sterile, closed workflow for preparing small volume cell therapy batches. It is intended for use in autologous and other cell therapy processes, where maintaining dose accuracy, sterility, and batch to batch consistency is critical.

Thermo Fisher Scientific

The post Automated Fill and Finish System appeared first on GEN – Genetic Engineering and Biotechnology News.

3D Light Sheet Microscope

Leica Microsystems has introduced the Viventis SCAPE light sheet microscope, a system designed for rapid 3D imaging of live biological samples. The instrument uses SCAPE technology to capture fast volumetric images under gentle conditions, allowing researchers to follow time critical cellular and tissue processes without compromising specimen viability. Because it is compatible with standard sample carriers, the system supports consistent handling and makes experiments easier to repeat and compare across conditions.

Leica Microsystems

The post 3D Light Sheet Microscope appeared first on GEN – Genetic Engineering and Biotechnology News.

STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more

ROME — Julia Vitarello, whose daughter Mila eight years ago received a bespoke medicine designed for her particular disease-causing mutation, said this week that she is in the process of starting a new company to try to create these individualized therapies at scale.

Vitarello’s previous effort, called EveryONE Medicines, recently folded in part because new Food and Drug Administration guidance encouraging the development of customized therapies did not go far enough in creating a pathway to satisfy EveryONE’s investors, Vitarello said. 

Now Vitarello and collaborators are looking for new funders. 

Continue to STAT+ to read the full story…

Brain Glucose Levels Act as a Metabolic Switch for Myelin Formation

Scientists have long known that myelin doesn’t appear everywhere in the brain at once. Some regions myelinate early, others much later, and the timing shapes everything from motor development to cognitive maturation. What has remained elusive is why these regional differences emerge in the first place. A new study in Nature Neuroscience, titledGlucose-dependent spatial and temporal modulation of oligodendrocyte progenitor cell proliferation via ACLY-regulated histone acetylation,” points to an unexpected driver: shifting glucose levels that act as a metabolic switch, telling progenitor cells when to divide and when to mature into myelin‑forming oligodendrocytes.

The work, led by researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC), maps glucose distribution across the developing mouse brain and reveals that these spatial and temporal fluctuations are not just metabolic background noise. They are instructive signals. “Regions with high glucose levels exhibited greater OPC proliferation and histone acetylation than regions with low glucose,” the authors wrote in the paper’s abstract, suggesting glucose as a key regulator of oligodendrocyte progenitor cell (OPC) population dynamics.

Using MALDI imaging at the CUNY ASRC MALDI Imaging Core Facility, the team visualized glucose concentrations across brain regions during early development in mice. Areas rich in glucose contained actively dividing OPCs, while regions with lower glucose levels harbored cells beginning to differentiate into oligodendrocytes. This pattern suggested that glucose availability helps determine whether OPCs expand their numbers or transition toward myelin production.

“Our findings show that glucose is not just fuel for the brain, it’s also a signal for the cells to divide,” said lead author Sami Sauma, PhD, a postdoctoral researcher with the CUNY ASRC Neuroscience Initiative. “When glucose levels are high in a particular brain region, progenitors use it to drive proliferation. As glucose levels shift, the same cells switch gears and begin maturing.”

An enzyme, ATP‑citrate lyase (ACLY), which converts glucose‑derived citrate into acetyl‑CoA in the nucleus, is central to this process. This acetyl‑CoA fuels histone acetylation, activating genes required for cell proliferation. When the researchers deleted Acly in OPCs, the cells could no longer proliferate efficiently, leading to a temporary reduction in myelin due to decreased OPC numbers. Yet differentiation still occurred, thanks to a compensatory pathway: mature oligodendrocytes can generate acetyl‑CoA outside the nucleus from alternative fuels such as ketone bodies.

This metabolic flexibility proved more than a biochemical curiosity. When mice lacking ACLY in OPCs were placed on a ketogenic diet, their myelin deficits improved. “The same cell lineage interprets different metabolic signals at distinct stages of development,” said senior author Patrizia Casaccia, MD, PhD, founding director of the CUNY ASRC Neuroscience Initiative. “By understanding how glucose and alternative energy sources regulate proliferation and myelin formation, we are uncovering new metabolic strategies that could be harnessed to protect myelin in the developing brain.”

The developmental window examined in mice corresponds to roughly 32 to 40 weeks of human gestation—a period when premature infants are particularly vulnerable to white‑matter injury. The findings raise the possibility that metabolic support during this stage could help preserve the progenitor cells responsible for building myelin. They may also inform future approaches to repairing myelin in disorders such as multiple sclerosis.

The post Brain Glucose Levels Act as a Metabolic Switch for Myelin Formation appeared first on GEN – Genetic Engineering and Biotechnology News.

Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood

J. Craig Venter, a scientist whose relentless ambition helped turn genetics from an artisanal trade into an industrialized information machine, died Wednesday at 79. The cause was side effects of a cancer treatment.

Along the way, he did things that can only be described as really cool. He raced against a government-funded project to sequence the first human genome, grabbing headlines around the world; traveled the ocean in his sailboat collecting genetic information about sea life; and removed a bacterium’s genome and rebooted the organism with an identical set of genes he and his team had synthesized. He drove fast cars, drank red wine, and pissed people off.

Read the rest…

STAT+: Hair-raising trial results, and Servier’s M&A wishlist

Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena?

We get into all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast.

Veradermics CEO Reid Waldman joined us to discuss his company’s data, and why hair loss is such a trendy topic in biotech. Then, Servier Pharmaceuticals CEO David Lee joined us to discuss the company’s acquisition of Day One Biopharmaceuticals. The hosts also discussed the latest news in biotech.

Continue to STAT+ to read the full story…

Genomics Pioneer and Life Sciences Entrepreneur J. Craig Venter Dies at 79

J. Craig Venter, PhD, the founder, board chair, and CEO of the J. Craig Venter Institute (JCVI) has died in San Diego following a brief hospitalization for unexpected side effects that arose from the treatment of a recently diagnosed cancer, noted the JCVI in a press statement.

Venter helped define modern genomics and launch the field of synthetic biology. He was skillful in building interdisciplinary teams, pushing for new ideas and faster methods, and insisting that discovery should translate into real-world impact. He was also a major advocate for strong federal science funding and for partnerships that accelerate progress across government, academia, and industry.

“Craig believed that science moves forward when people are willing to think differently, move decisively, and build what doesn’t yet exist,” said Anders Dale, PhD, president of JCVI. “His leadership and vision reshaped genomics and helped ignite synthetic biology. We will honor his legacy by continuing the mission he built—advancing genomic science, championing the public investments that make discovery possible, and partnering broadly to turn knowledge into impact.”

“Venter has been recognized as an essential force in the impetus to evolve genomics from a slow, academic discipline into a fast-moving, data-driven, and commercially relevant enterprise, leaving a lasting imprint on biotechnology, medicine, and synthetic biology,” says John Sterling, GEN’s Editor in Chief, who has known and worked editorially with Venter over the past 35 years.

“Venter was controversial and often challenged the scientific orthodoxy, with critics accusing him of hype and going overboard on privatization. To many, he was a visionary focusing on technological acceleration and blending academic science with the zeal of an entrepreneur. Supporters saw him as a pioneer who sped up genomics by years.”

At the NIH, he played a key role in driving gene discovery using expressed sequence tags (ESTs), enabling rapid identification of large numbers of human genes and accelerating genome mapping efforts. He went on to lead efforts that, along with the NIH, produced the first draft sequences of the human genome, a milestone that helped usher biology into the digital age. He and colleagues later published the first high-quality diploid human genome, demonstrating the importance of capturing genetic variation inherited from both parents.

In synthetic biology, Venter and his teams constructed the first self-replicating bacterial cell controlled by a chemically synthesized genome—proof that genomes could be designed digitally, built from chemical components, and “booted up” to run a living cell. He also pursued scientific discovery at global scale.

Through the Sorcerer II Global Ocean Sampling Expedition, Venter and his teams used metagenomics to reveal amazing microbial diversity, reporting the discovery of millions of new genes and expanding the known universe of protein families—work that deepened understanding of the ocean microbiome and its impact on planetary systems.

Beyond his scientific achievements, and in addition to founding the JCVI, he also co-founded Synthetic Genomics, Human Longevity, and most recently Diploid Genomics, advancing efforts to translate genomics and synthetic biology into tools for the benefits of human health and environmental sustainability.

 

The post Genomics Pioneer and Life Sciences Entrepreneur J. Craig Venter Dies at 79 appeared first on GEN – Genetic Engineering and Biotechnology News.

Exclusive eBook: Inside the stealthy startup that pitched brainless human clones

The ultimate plan to live forever is a brand new body.

This subscriber-only eBook explores R3 Bio, a small startup that has pitched a startling and ethically charged vision for “brainless clones” to serve the role of backup human bodies.

by Antonio Regalado March 20, 2026

Related Stories:

Access all subscriber-only eBooks:

Advanced Neural Probes Reveal Predictable Patterns in Epileptic Brain Activity

In addition to suffering seizures, many people with epilepsy also experience bursts of abnormal brain activity called interictal epileptiform discharges (IEDs). These can happen thousands of times a day and interfere with attention, memory, language, and sleep. New data from a study led by scientists at University of California, San Francisco (UCSF) shows that these brain blips are not random events as once thought. The data shows that they unfold in a predictable pattern that can be detected before they occur, suggesting it may be possible to prevent them. 

Details of their work are published in Nature Neuroscience in a paper titled “Laminar organization of cellular microcircuits modulating human interictal epileptiform discharges.” In it, the scientists explain that they used a high-resolution technology recently adapted for humans that records individual neuron activity to track more than 1000 neurons in four patients undergoing surgery for epilepsy. The so-called Neuropixel probes provide “a view into new ways we might address a debilitating aspect of epilepsy that we haven’t been able to tackle,” said Jon Kleen, MD, PhD, an associate professor of neurology at UCSF and co-senior author of the study. 

Preventing brain blips would be a boon for patients’ quality of life because over time, the effects of these mental disruptions can be significant and may account for some of the cognitive impairment experienced by about half of people with epilepsy. 

Neuropixels probes, which are thin devices lined with hundreds of sensors, are designed to record activity throughout the human cortex. This means that unlike current sensors which are limited to brain signals on the surface of the brain, Neuropixels can provide a three-dimensional view of brain activity. For the study, the scientists implanted the probes seven millimeters deep into the part of the brain where patients’ seizures originate—this is the tissue that surgeons typically remove to reduce epilepsy symptoms. 

Inserting the probes here made it possible to observe what happened in the neurons before, during, and after each IED. While seizures appear as a burst of neurons firing in synchrony, when IEDs occur, they unfold sequentially. Specifically, one set of neurons was active about a second before the IED started followed by another set that generated the sharp electrical spike at its peak, and then a third set became active as the IED faded. “We could see individual neurons that were just microns apart from each other playing different roles in the process,” said Alex Silva, the study’s first author and a medical student and doctoral candidate in the UCSF-UC Berkeley Joint PhD program in bioengineering. “It was really striking.”

Previous studies have demonstrated that most neurons involved in IEDs are used in normal cognitive processing. According to this study, nearly 80% of the neurons involved in IEDs were also involved in language and perception. Current implantable devices for epilepsy may be able to help. They include closed loop neurostimulators that can detect abnormal brain activity and deliver electrical pulses that interrupt it. So in the case of IEDs, devices that monitor single neurons could use the activity of the first set of neurons announcing the arrival of the abnormal pattern as a warning signal. “That would be a major step forward, changing treatment from reactively responding to abnormal brain bursts to proactively preventing them in the first place,” Kleen said.

The post Advanced Neural Probes Reveal Predictable Patterns in Epileptic Brain Activity appeared first on GEN – Genetic Engineering and Biotechnology News.

This startup’s new mechanistic interpretability tool lets you debug LLMs

The San Francisco–based startup Goodfire just released a new tool, called Silico, that lets researchers and engineers peer inside an AI model and adjust its parameters—the settings that determine a model’s behavior—during training. This could give model makers more fine-grained control over how this technology is built than was once thought possible.

Goodfire claims Silico is the first off-the-shelf tool of its kind that can help developers debug all stages of the development process, from building a data set to training a model.

The company says its mission is to make building AI models less like alchemy and more like a science. Sure, LLMs like ChatGPT and Gemini can do amazing things. But nobody knows exactly how or why they work, and that can make it hard to fix their flaws or block unwanted behaviors. 

“We saw this widening gap between how well models were understood and just how widely they were being deployed,” Goodfire’s CEO, Eric Ho, tells MIT Technology Review in an exclusive chat ahead of Silico’s release. “I think the dominant feeling in every single major frontier lab today is that you just need more scale, more compute, more data, and then you get AGI [artificial general intelligence] and nothing else matters. And we’re saying no, there’s a better way.”

Goodfire is one of a small handful of companies, including industry leaders Anthropic, OpenAI, and Google DeepMind, pioneering a technique known as mechanistic interpretability, which aims to understand what goes on inside an AI model when it carries out a task by mapping its neurons and the pathways between them. (MIT Technology Review picked mechanistic interpretability as one of its 10 Breakthrough Technologies of 2026.)  

Goodfire wants to use this approach not only to audit models—that is, studying those that have already been trained—but to help design them in the first place.  

“We want to remove the trial and error and turn training models into precision engineering,” says Ho. “And that means exposing the knobs and dials so that you can actually use them during the training process.”

Goodfire has already used its techniques and tools to tweak the behaviors of LLMs—for example, reducing the number of hallucinations they produce. With Silico, the company is now packaging up many of those in-house techniques and shipping them as a product.

The tool uses agents to automate much of the complex work. “Agents are now strong enough to do a lot of the interpretability work that we were doing using humans,” says Ho. “That was kind of the gap that needed to be bridged before this was actually a viable platform that customers could use themselves.”

Leonard Bereska, a researcher at the University of Amsterdam who has worked on mechanistic interpretability, thinks Silico looks like a useful tool. But he pushes back on Goodfire’s loftier aspirations. “In reality, they are adding precision to the alchemy,” he says. “Calling it engineering makes it sound more principled than it is.”

Mapping models

Silico lets you zoom in on specific parts of a trained model, such as individual neurons or groups of neurons, and run experiments to see what those neurons do. (Assuming you have access to the model’s inner workings. Most people won’t be able to use Silico to poke around inside ChatGPT or Gemini, but you can use it to look at the parameters inside many open-source models.) You can then check what inputs make different neurons fire, and trace pathways upstream and downstream of a neuron to see how other neurons affect it and how it affects other neurons in turn.

For example, Goodfire found one neuron inside the open-source model Qwen 3 that was associated with the so-called trolley problem. Activating this neuron changed the model’s responses, making it frame its outputs as explicit moral dilemmas. “When this neuron’s active, all sorts of weird things happen,” says Ho.

Pinpointing the source of odd behavior like this is now pretty standard practice. But Goodfire wants to make it easier to adjust that behavior. Using Silico, developers can now adjust the parameters connected to individual neurons to boost or suppress certain behaviors.

In another example, Goodfire researchers asked a model whether a company should disclose that its AI behaves deceptively in 0.3% of cases, affecting 200 million users. The model said no, citing the negative business impact of such a disclosure.

By looking inside the model, the researchers found that boosting neurons that were found to be associated with transparency and disclosure flipped the answer from no to yes nine out of 10 times. “The model already had the ethical reasoning circuitry, but it was being outweighed by the commercial risk assessment,” says Ho.

Tweaking the values of a model in this way is just one approach. Silico can also help steer the training process by filtering out certain training data to avoid setting unwanted values for certain parameters in the first place.   

For example, many models will tell you that 9.11 is greater than 9.9. Looking inside a model to see what’s going on might reveal that it is being influenced by neurons associated with the Bible, in which verse 9.9 comes before 9.11, or by code repositories where consecutive updates are numbered 9.9, 9.10, 9.11 and so on. Using this information, the model can be retrained to make it avoid its “Bible” neurons when doing math.

By releasing Silico, Goodfire wants to put techniques previously available to a few top labs into the hands of smaller firms and research teams that want to build their own model or adapt an open-source one. The tool will be available for a fee determined on a case-by-case basis according to customers’ requirements (Goodfire declined to give specific pricing details).

“If we can make training models a lot more like building software, there’s no reason why there can’t be many more companies designing models that fit their needs,” says Ho.

Bereska agrees that tools like Silico could help firms build more trustworthy models. These techniques could be essential for safety-critical applications in health care and finance, he says.

“Frontier labs already have internal interpretability teams,” he adds. “Silico arms the next tier of companies, where the value is not having to hire interpretability researchers.”